Drug Profile
Research programme: small interfering RNA therapeutics - POLYPID
Latest Information Update: 28 Apr 2021
Price :
$50
*
At a glance
- Originator POLYPID
- Class Antineoplastics; Small interfering RNA
- Mechanism of Action RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Cancer
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Apr 2021 No recent reports of development identified for preclinical development in Cancer in Israel (Controlled release)
- 29 Mar 2017 Research programme: small interfering RNA therapeutics - POLYPID is available for licensing as of 29 Mar 2017.
- 29 Mar 2017 Preclinical trials in Cancer in Israel (unspecified route)